Billion dollar target for biologics biz by FY22 unrealistic, but we would soon return to high growth trajectory: Kiran Mazumdar Shaw – Economic Times
On an annualised level, our biologics business grew 21% from Rs 2,315 crore to Rs 2,800 crore this fiscal. At a consolidated level, we grew 14% from Rs 6,462 crore to Rs 7,360 crore, says Kiran Maz…
